• Sarah Howell, Ph.D., Chief Executive Officer and Executive Director

    Sarah Howell has been Chief Executive Officer of Arecor since 2015.

    Through her leadership, Arecor has grown significantly into a publicly listed clinical stage biopharmaceutical company. Since her appointment, Sarah has led Arecor through a period of continued growth and transformation, playing an instrumental role in progressing its proprietary pipeline and strengthening important collaborations with global partners.

    Sarah has a background in clinical and commercial pharmaceutical product development, manufacturing, supply and licensing across a range of product types and therapeutic areas, with previous senior roles in the pharmaceutical industry including Vice President CMC & Technical Development at BTG Plc., and Director of Outsourced Manufacturing at UCB-Celltech. Sarah holds a BSc in Chemistry from the University of Birmingham and a Ph.D. in Physical Organic Chemistry from the University of St Andrews.


  • Susan Lowther, Chief Financial Officer and Executive Director/Company Secretary

    Susan Lowther was appointed Chief Financial Officer and Company Secretary at Arecor in 2019 and has significant financial leadership experience across a broad range of public and private life science companies.

    Previously she was CFO at IXICO plc where she raised growth capital as part of a path to profitability strategy. At Novacyt S.A. she oversaw the acquisition of Lab21 Limited, she was CFO at BioWisdom Limited until its acquisition by Instem Plc, and Finance Director of RiboTargets Limited, from start-up until its acquisition by Vernalis plc. Susan’s life-sciences career started at Celltech Group plc and included Head of Finance at Lonza Biologics (previously Celltech Biologics).

    Susan has been a member of executive boards since 1997 and a Fellow of the Chartered Institute of Management Accountants since 2003. She is a Non-Executive Director and Chair of the Audit & Risk Committee of BiVictriX Therapeutics plc.

  • Jan Jezek, Ph.D., Chief Scientific Officer

    Jan Jezek has been Chief Scientific Officer of Arecor since 2007 and has led R&D for the proprietary protein stabilisation technologies of the company’s Arestat™ platform and their application to commercial therapeutic products. Jan is responsible for R&D activities, platform development and IP strategy.

    Previously, he was a Principal Scientist at Insense Limited, a spin-out from Unilever, where he was responsible for the development of novel medical devices, taking them from concept to market.

    Jan holds a joint Doctorate from the University of Bedfordshire and the University of Chemical Technology, Prague. He is a member of the Scientific Advisory Board of the Centre of Excellence in Biopharmaceuticals (University of Manchester) and is an active member of the Formulation Science & Technology Group (FSTG) at the Royal Society of Chemistry and the Biopharmaceutical Group at the Academy of Pharmaceutical Sciences (APS).

  • Manjit Rahelu, Ph.D., Chief Business Officer

    Manjit is an accomplished strategic deal maker, with a strong scientific background and over 25 years of technical, commercial and financial experience across large and mid-sized pharmaceutical and biotechnology companies.

    He joined Arecor in 2023, after founding and serving as Partner at Alcheme Advisors, supporting early-stage businesses on a variety of business development, strategy and optimisation projects. Prior to this, Manjit held the role of Chief Business Officer and Chief Operating Officer at Calchan, a UK biotechnology company, where he oversaw the shaping and implementing of the organisation’s strategy, processes, and infrastructure, as well as leading business development efforts.

    Manjit also served as Vice President Business Development at Convergence Pharmaceuticals, where, as a member of the leadership team, he helped to shape the company’s growth strategy, with primary responsibility for leading business development initiatives to commercialise its chronic pain assets. Earlier in his career, he held positions with increasing responsibilities at a variety of life science companies including Sandoz, Pfizer, Sanofi and UCB.

  • David Gerring, Senior VP, Development

    David has 15 years’ experience in pharmaceutical product and analytical development, as well as significant regulatory and quality experience. He is VP, Development at Arecor, with a wide range of responsibilities, including: scientific strategy, project management, facilities, health & safety, quality and client procurement, grant and internal product development management.

    He has held senior roles at Immunocore and Emergent BioSolutions and his experience includes 5 years at UCB, whilst in a scientific and regulatory capacity. There, he focused on the development and successful licensure of Cimzia. He headed up process and analytical development at BTG, managing CMC for several recombinant products, including successful INDs and licensures.




  • Helen Parris, Senior VP, Commercial and General Manager of Tetris Pharma Ltd

    Helen has over 20 years of scientific, commercial and government affairs experience across several international biopharmaceutical companies. Before joining Tetris Pharma, Helen served as General Manager of Northern Markets (UK, Netherlands and Nordics) at Albireo Pharma, Inc., which was acquired by Ipsen in March 2023 and where she played a key role in establishing and building the regional affiliate.

    Previously, Helen worked for 14 years at Gilead Sciences, where she held multiple positions, including Executive Director of EMEA, Global Affairs Regional Lead, where she was instrumental in broadening patient access to treatment. Whilst at Gilead, Helen led the launch of several transformational products in Europe developing critical launch strategies and expanding commercial opportunities.

    Helen holds a BSc in Biology from York University, a PhD from Leeds University, and an MBA from Henley Management College.